BridgeMD
New treatment option for Multiple Sclerosis
Official title Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
ClinicalTrials.gov ID: NCT06495138
What this study is testing
- What it's testing
- The study aims to study the effects of a novel treatment for vestibular symptoms in people with multiple sclerosis. The main objective is to determine whether daily personalized gaze stabilization training is more beneficial than intermittent gaze stability training in people with multiple sclerosis.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 89. Healthy volunteers may be eligible.
You may be able to join if
- Neurologist-confirmed diagnosis of primary progressive or relapsing and remitting MS per The 2017 Revision of the McDonald Criteria and the Magnetic...
- Fluent in speaking and understanding English
- people with multiple sclerosis have self-reported vestibular symptoms of dizziness, imbalance, and/or a history of at least two falls in the prior 12...
You likely can't join if
- Clinically isolated syndrome or radiologically isolated syndrome.
- Worsening MS symptoms during the prior 60 days
- Immunotherapy change in the prior 60 days
- Self-reported cognitive impairment that limits independence with basic and instrumental activities of daily living
- Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 90 mmHg at rest
- Static visual acuity with correction of worse than 1.0 logMAR
See the full eligibility criteria
- Neurologist-confirmed diagnosis of primary progressive or relapsing and remitting MS per The 2017 Revision of the McDonald Criteria and the Magnetic Resonance Imaging in MS, or a healthy volunteer without a diagnosis of...
- Fluent in speaking and understanding English
- people with multiple sclerosis have self-reported vestibular symptoms of dizziness, imbalance, and/or a history of at least two falls in the prior 12 months
- Clinically isolated syndrome or radiologically isolated syndrome.
- Worsening MS symptoms during the prior 60 days
- Immunotherapy change in the prior 60 days
- Self-reported cognitive impairment that limits independence with basic and instrumental activities of daily living
- Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 90 mmHg at rest
- Static visual acuity with correction of worse than 1.0 logMAR
- Manifest ocular misalignment ≥ 5 diopters (e.g., tropia, lazy eye, strabismus}
- Convergence insufficiency
- Intra-nuclear ophthalmoplegia
- Vestibular Migraine
- Major orthopedic conditions that limit cervical spine range of motion or that alter walking
- Self-reported current or potential for pregnancy during enrollment
- Ongoing participation in vestibular rehabilitation for dizziness
The study team makes the final eligibility decision.
Where it's taking place
- Atlanta, Georgia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 89 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Atlanta, Georgia, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.